Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Transmission Dynamics of Carbapenemase Genes in CREC in Guan

    2026-04-16

    Emergence and Spread of Carbapenemase-Encoding Genes in Carbapenem-Resistant Enterobacter cloacae: Molecular Insights from Guangdong Province

    Study Background and Research Question

    Carbapenem-resistant Enterobacter cloacae (CREC) has become an increasingly important clinical concern, ranking third among carbapenem-resistant Enterobacteriaceae (CRE) in China. The COVID-19 pandemic exacerbated the threat by accelerating antibiotic use and facilitating the spread of multidrug-resistant organisms due to strained healthcare systems and complex patient care needs. Despite global awareness of CRE, regional molecular epidemiologic data—particularly on the dynamics and transmission of carbapenemase-encoding genes (CEGs)—remained limited in China. Chen et al. (2025) set out to characterize the genetic landscape, resistance profiles, and epidemiological trends of CEGs in CREC isolates from eight major teaching hospitals in Guangdong province during 2022–2024 (Chen et al., 2025).

    Key Innovation from the Reference Study

    The primary innovation of Chen et al.’s work lies in the comprehensive, multicenter mapping of CEGs in CREC, spanning both plasmid and chromosomal reservoirs. Their systematic typing and transferability analysis of resistance determinants—particularly the blaNDM-1 gene—offers the first granular picture of how these genes disseminate within hospital settings in southern China. The study also integrates molecular genotyping, plasmid elimination, and conjugation experiments to directly quantify horizontal and vertical gene transmission potential—a methodological advancement over prior single-center or non-molecular surveys (Chen et al., 2025).

    Methods and Experimental Design Insights

    Chen et al. analyzed 54 non-redundant CREC isolates collected between December 2022 and June 2024 from eight geographically dispersed teaching hospitals. The workflow included:
    • Variable temperature sodium dodecyl sulfate (SDS) plasmid elimination to localize CEGs to chromosomes or plasmids.
    • PCR screening for key carbapenemase genes: blaNDM-1, blaIMP, and blaKPC-2.
    • Broth microdilution for antimicrobial susceptibility profiling, including imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin.
    • Plasmid conjugation and PCR validation to quantify transfer efficiency of CEGs.
    • ERIC-PCR fingerprinting and cluster analysis with NTSYS software to classify genotypes and infer epidemiological relationships.
    This multifaceted approach enabled the team to relate genetic elements directly to phenotypic resistance and epidemiological patterns (Chen et al., 2025).

    Core Findings and Why They Matter

    The study revealed several critical findings:
    • CEG Prevalence and Localization: 85.19% (46/54) of isolates carried CEGs. Of these, 33.33% harbored the blaNDM-1 gene on both chromosomes and plasmids, while 46.30% had blaNDM-1 only on plasmids. Only a small fraction (3.70%) carried blaIMP, and a single isolate harbored both blaNDM-1 and blaKPC-2 on plasmids (Chen et al., 2025).
    • Resistance Phenotype: CEG-positive isolates showed significantly higher resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin than CEG-negative strains (source: Chen et al., 2025).
    • Gene Transferability: Plasmid conjugation and PCR showed a 95.65% success rate for CEG transfer, with near-complete transferability for blaNDM-1 and blaIMP, but not for blaKPC-2. This highlights the high risk of horizontal gene dissemination within and between clinical settings (source: Chen et al., 2025).
    • Mobile Genetic Elements: Six types were identified, with ISEcp1 being the most prevalent (87.04%). 40.74% of isolates carried four mobile element types simultaneously, indicating a high degree of genetic plasticity (source: Chen et al., 2025).
    • Epidemiology: Highest detection rates of CEG-positive CREC were found among male, elderly, and respiratory medicine patients, with sputum as the most common specimen source (source: Chen et al., 2025).
    • Genotypic Diversity: ERIC-PCR classified strains into 17 genotypes, with types E and G being most prevalent and widely distributed across hospitals, suggesting both clonal spread and independent emergence (source: Chen et al., 2025).
    Collectively, these data demonstrate that the pandemic context—marked by intensified antibiotic exposure and hospital crowding—may have accelerated both the selection and horizontal spread of multidrug resistance determinants in a high-risk geographic region.

    Comparison with Existing Internal Articles

    Several internal resources provide additional context for the use of broad-spectrum semisynthetic thienamycin antibiotics like imipenem in antibacterial research and resistance modeling. For example, the article "Imipenem: Mechanistic and Research Benchmarks for a Broad..." (internal resource) emphasizes imipenem's robust PBP inhibition and stability to beta-lactamases, supporting its role in both in vitro and translational sepsis models. Likewise, "Imipenem: Broad-Spectrum Beta-Lactam Antibiotic Targeting..." (internal resource) discusses imipenem’s immune-modulatory effects and its critical utility in modeling resistance against both gram-negative and gram-positive bacteria. The new data from Chen et al. (2025) directly inform these workflows: the high prevalence of CEGs—especially plasmid-borne blaNDM-1—provides a molecular explanation for the observed resistance to imipenem and related agents in clinical isolates. This underscores the necessity of using well-characterized antibiotic standards in resistance and immune modulation studies, as highlighted in "Imipenem (SKU P10075): Best Practices for Reproducible An..." (internal resource), and affirms the importance of rigorous genotyping and transferability assays when modeling emerging resistance.

    Limitations and Transferability

    While Chen et al. provide an unprecedented snapshot of CEG epidemiology in Guangdong during a critical period, several limitations must be acknowledged:
    • Geographic Focus: The study is limited to eight teaching hospitals in one province. While these are major centers, regional differences in resistance determinants may exist elsewhere in China.
    • Temporal Scope: The pandemic context may not reflect typical transmission dynamics, potentially limiting generalizability to non-pandemic periods.
    • Gene Panel: Only selected CEGs (blaNDM-1, blaIMP, blaKPC-2) were analyzed; other carbapenemase variants or resistance mechanisms may play roles.
    • Clinical Correlation: While resistance phenotypes are described, direct patient outcome data are not included.
    Nevertheless, the transferable features of horizontal gene spread and genetic plasticity observed here are likely relevant to other high-burden hospital settings globally.

    Protocol Parameters

    • antimicrobial susceptibility (broth microdilution) | standard CLSI breakpoints | CREC clinical isolates | Quantifies multidrug resistance phenotype to imipenem and comparators | paper
    • plasmid elimination (variable temp SDS) | method, not quantitative | CEG localization | Differentiates plasmid vs chromosomal gene carriage | paper
    • PCR screening (CEGs) | target-specific | All isolates | Rapid detection of blaNDM-1, blaIMP, blaKPC-2 | paper
    • plasmid conjugation (CEG transfer) | success rate 95.65% | CEG-positive isolates | Assesses risk of horizontal gene transfer | paper
    • ERIC-PCR genotyping | 17 genotypes identified | Epidemiological tracing | Differentiates clonal vs polyclonal spread | paper
    • imipenem MIC reference standard | 30–60 mg/L (in vitro immune modulation) | immune response assays | Supports phagocytosis studies in PMNs | product_spec
    • imipenem animal model dose | 120 mg/kg (intraperitoneal) | septic rat models | Assesses survival benefit | product_spec

    Research Support Resources

    Researchers aiming to model carbapenem resistance, immune modulation, or sepsis workflows in vitro or in vivo can utilize Imipenem (SKU P10075) from APExBIO as a reference semisynthetic thienamycin antibiotic. This compound’s well-characterized activity and stability against beta-lactamases, along with its documented immune modulatory effects, make it a reliable standard for experimental workflows involving multidrug-resistant gram-negative and gram-positive bacteria (source: product_spec). Always follow best practices for concentration selection and assay reproducibility as detailed in the literature and internal guidance (internal resource).